B-cell Biology of Mucosal Immune Protection from SIV Challenge

描述（由申请人提供）：开发一种安全有效的HIV-1疫苗对于遏制目前影响全球3000多万人的主要性传播疾病的传播至关重要。虽然最近的痘病毒蛋白免疫原效力试验赋予适度的保护，从收购，保护的相关性是未知的。在恒河猴的SIV感染模型中，高达70%的动物，用GM-CSF增强的DNA引发、MVA加强接种，然后进行异源（E660）、多次低剂量直肠攻击，被保护免于获得，并且保护的明确相关性是E660 Env结合抗体亲合力。Emory Consortium for B-Cell Biology of Mucobacterium Immune Protection from SIV Challenge，使用高度合作的方法，将通过先进的免疫学和系统生物学方法来定义增强抗体亲和力和保护的潜在机制。该联盟将包括四个研究项目和四个科学支持核心，以及一个实现这一目标的行政核心。项目1将确定GM-CSF介导增强对低剂量SIV阴道攻击的保护的机制，并将确定添加优化的蛋白质加强是否进一步增强保护。项目2将研究TLR-4和TLR-7配体的潜在和潜在机制，这些配体以新型合成纳米颗粒制剂形式递送，最近显示出显著改善对流感HA的抗体应答，以提高保护性粘膜B细胞和T细胞对SIV VLP的应答质量。项目3将确定GM-CSF和纳米颗粒递送的TLR配体佐剂对滤泡T细胞的作用及其在塑造体液免疫应答质量中的功能，而项目4将类似地研究这些佐剂方法激活具有B细胞辅助功能的产生IL-21的N{BH}嗜中性粒细胞亚群的潜力。这些项目将得到NHP核心的支持，该核心将为研究提供和维持具有遗传特征的雌性猕猴。额外的核心将允许在单细胞和粘膜分泌物水平上表征抗病毒抗体应答，B细胞生物标志物核心将开发用于定义该恒河猴模型中B细胞应答的独特试剂。行政核心将通过数据库和储存库管理确保项目与核心之间的有效沟通和协作，并将负责保持时间表、财务责任和传播研究成果。

DESCRIPTION (provided by applicant): The development of a safe and effective vaccine against HIV-1 is critical for curtailing the spread of a primarily sexually transmitted disease that is now affecting more than 30 million persons worldwide. While a recent poxvirus-protein immunogen efficacy trial conferred modest protection from acquisition, the correlates of protection are unknown. In the SIV infection model in Rhesus macaques, up to 70% of animals, vaccinated with GM-CSF enhanced DNA priming, MVA boosted, then subjected to a heterologous (E660), multiple low dose rectal challenge, were protected from acquisition and a clear correlate of protection was E660 Env binding antibody avidity. The Emory Consortium for B-Cell Biology of Mucosal Immune Protection from SIV Challenge, using highly collaborative approaches, will define through advanced immunological and systems biology approaches the underlying mechanisms for enhanced antibody avidity and protection. The Consortium will incorporate four research projects and four science support cores, in addition to an Administrative core to achieve this goal. Project 1 will identify the mechanisms by which GM-CSF mediates enhanced protection from low dose SIV vaginal challenge, and will determine whether addition of an optimized protein boost further enhances protection. Project 2 will investigate the potential and underlying mechanism for TLR-4 and TLR-7 ligands, delivered in a novel synthetic nanoparticle formulation and recently shown to dramatically improve antibody responses to influenza HA, to enhance the quality of protective mucosal B-cell and T-cell responses to SIV VLPs. Project 3 will determine the effects of GM-CSF and nanoparticle delivered TLR ligand adjuvants on follicular T-cells and their function in molding the quality of the humoral immune response, while Project 4 will similarly investigate the potential for these adjuvanting approaches to activate a subset of IL-21 producing N{BH} neutrophils equipped with B cell helper function. The projects will be supported by an NHP Core, which will provide and maintain genetically characterized female macaques for the studies. Additional Cores will allow characterization of the antiviral antibody response at the level of single cells and mucosal secretions, and a B-cell biomarker core will develop unique reagents for defining the B-cell response in this rhesus model. The Administrative Core will ensure effective communication and collaboration between projects and Cores through database and repository management and will be responsible for maintaining timelines, fiscal responsibility, and dissemination of research results.